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have been a cross-species infection from mice to bats in 
the same habitat.
Although bats rarely come in direct contact with hu-
mans, humans can come into more frequent contact with 
bat urine and feces and, in the case of fruit bats, bat sa-
liva through partially eaten fruits. Bats in the Middle East 
are not eaten for food but are occasionally hunted. In this 
study, HKU9-related viruses were detected in apparently 
healthy fruit bat species from Egypt and Lebanon and ap-
pear to cause systemic infection. HKU9-related viruses are 
not known to cause human disease. MERS-CoV was not 
detected in bats sampled in this study. More surveillance 
for bat CoVs in the Middle East is needed, and the zoonotic 
potential for bat-CoVs requires further study.
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To the Editor: Ebola virus (EBOV) disease is usually 
an acute illness, but increasing evidence exists of persistent 
infections and post-Ebola syndromes. We report a case of 
EBOV encephalitis.
A 30-year-old woman with no known EBOV contact 
sought treatment at an Ebola isolation unit in Freetown, Si-
erra Leone, on January 1, 2015 (day 7 of illness). She was 
afebrile and weak, but ambulatory, with a history of fever, 
vomiting, diarrhea, headache, and muscle and joint pain. 
According to local protocol, she was given oral antimalari-
al, antimicrobial, and antiemetic drugs and oral rehydration 
therapy. On day 8 of illness, after testing EBOV PCR–posi-
tive (cycle threshold [Ct] value of 23.5) (1), she was given 
intravenous ceftriaxone (2 g) for 7 days, artesunate (180 
mg) for 3 days, and Ringer’s lactate (4–6 L) with supple-
mental KCl for 5 days.
During days 13–15, the patient improved, moving 
independently and talking. On day 16, she became con-
fused; by day 20, she was unresponsive to voices. Intra-
venous ceftriaxone (2 g) and artesunate (180 mg) were 
administered for an additional 7 and 3 days, respectively. 
On days 28 and 29, she was still unconscious; serum PCR 
test results on both days were negative for EBOV. On day 
29, she was transferred to Connaught Hospital in Free-
town, where she had a Glasgow Coma Scale score of 9/15 
(E3, V1, M5) but no localizing or focal signs. She was 
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given intravenous fluconazole (800 mg 1×/d). Admis-
sion blood test results showed anemia, elevated alanine 
aminotransferase and C-reactive protein, and low creati-
nine (online Technical Appendix, http://wwwnc.cdc.gov/
EID/article/22/1/15-1212-Techapp1.pdf). HIV test results 
were negative. 
On day 34, large-joint polyarthritis of the right shoul-
der, left elbow, and left knee developed. Affected joints ap-
peared normal on radiographs, and synovial fluid (15 mL) 
from the left knee was EBOV PCR negative. She was given 
diclofenac (50 mg 2×/d) and 1 intramuscular dose of meth-
ylprednisolone (80 mg). Concurrent blood PCR on day 34 
was negative.
By day 41 she was more alert, although her family 
reported she had slowed responses. Lumbar puncture was 
performed; opening pressure (30 cm H2O) was elevated, 
and cerebrospinal fluid (CSF) was EBOV PCR–positive 
(Ct value 37.6), as determined by using the Public Health 
England in-house, optimized version of the Trombley assay 
(2) with a cutoff Ct value of 40. Concurrent catheter speci-
mens of urine and blood samples tested EBOV-negative. 
FilmArray (BioFire Diagnostics, Salt Lake City, UT, USA) 
testing showed methicillin-resistant Staphylococcus aureus 
and Klebsiella pneumoniae in CSF and mixed pathogens in 
urine. A computer tomographic scan image of the patient’s 
head showed substantial cerebral atrophy without hydro-
cephalus (Figure).
On day 44, an underarm sweat swab sample was PCR-
positive (Ct value 39.6) and a buccal swab sample PCR-
negative for EBOV. Ongoing painful synovitis was treated 
with an additional 80-mg intramuscular dose of methyl-
prednisolone. On day 51, a midstream urine sample was 
EBOV PCR–positive (Ct value 35.7), and an underarm 
sweat swab sample was EBOV PCR–negative. The patient 
was discharged; her family was advised to minimize con-
tact with her body fluids.
At follow-up on day 64, the patient’s family reported 
she had impaired short-term memory and ongoing slow-
ness. She had a score of 18/23 on the Mini–Mental State 
Examination, but general neurologic exam results were 
normal. A midstream urine test was still EBOV PCR–
positive (Ct value 39.6); PCR of her sweat swab sample 
was inhibited (online Technical Appendix). She was re-
ferred to the local survivors’ clinic; no contact cases 
were reported.
The depressed mental status and presence of EBOV 
in this case-patient’s CSF are consistent with encepha-
litis, a finding in autopsies of persons with Marburg 
virus infection (3,4) and in EBOV nonhuman primate 
models (5). The general atrophy seen in computer tomo-
graphic scan images is consistent with a rapidly devel-
oping complication of a diffuse inflammatory process. 
Given inadequate antimicrobial drug doses for menin-
gitis and clinical improvement, we believe methicil-
lin-resistant S. aureus and K. pneumoniae were CSF 
sample contaminants.
This case shows the brain’s immune privilege is in-
complete for EBOV and prompts a broader discussion re-
garding neurovirulence in Ebola virus disease. Our find-
ing that EBOV can be present in CSF, even after serum 
clearance, adds to the knowledge of neurologic symptoms 
in acute infection and of postinfectious sequelae in obser-
vational clinical studies (6–8). This finding raises the pos-
sibility that EBOV persistence elsewhere in the body, or in 
multiple organs, could be an indicator of or risk for central 



















Our report has limitations. We could not perform 
many blood chemistry tests, in-country virus cultures, or 
deep sequencing on samples. Likewise, diagnosis of coma 
was challenging because of the lack of CSF cell counts, 
biochemistry values, and paired EBOV IgG and IgM titers 
in CSF and blood.
This case raises the practical issue that Ebola treat-
ment requires understanding of multiorgan virologic and 
inflammatory complications; survivor care and research 
programs should screen for neurocognitive impairment and 
consider appropriate imaging. The case confirms previous-
ly reported intermittent EBOV PCR positivity in urine (9). 
The development of arthritis with synovitis, treated with 
corticosteroids, supports the diagnosis of reactive arthritis.
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To the Editor: During the early 20th century, at the 
end of World War I, and during World War II, louseborne 
relapsing fever (LBRF) caused by Borrelia recurrentis was 
a major public health problem, especially in eastern Europe 
and northern Africa (1,2). Currently, poor living conditions, 
famine, war, and refugee camps are major risk factors for 
epidemics of LBRF in resource-poor countries, such as 
those in the Horn of Africa (3,4).
Increased migration from resource-poor countries and 
war/violence create new routes for spread of vectorborne 
diseases. Recently, several cases of LBRF have been re-
ported among asylum seekers from Eritrea in the Nether-
lands, Switzerland, and Germany (5–8). All of these asy-
lum seekers had been in refugee camps in Libya or Italy. 
We report 3 cases of LBRF in migrants from Somalia to 
refugee camps in Sicily, Italy.
Patient 1 was a 13-old-boy from Somalia who arrived 
in Palermo, Italy, on July 11, 2015, after traveling though 
Libya. He was admitted to G. Di Cristina Hospital in Pal-
ermo 5 days after arrival because of high fever, headache, 
and general malaise, which developed 2 days after arrival. 
The patient had skin lesions on his fingers and legs and a 
conjunctival infection. He had thrombocytopenia (79,000 
platelets/μL [reference range 150 platelets/μL–400 plate-
lets/μL]), creatine phosphokinase level 967 mg/L [refer-
ence range 0.001 mg/L–0.10 mg/L], aspartate aminotrans-
ferase level 30 U/L (reference value 37 U/L), and alanine 
aminotransferase level 21 U/L (reference value 41 U/L). 
He was given ceftriaxone (2 g/d) and intravenous hydra-
tion. His conditions worsened ≈10 hours after treatment: 
high fever (temperature 40°C), chills, and profuse sweat-
ing (Jarish-Herxheimer reaction). The patient recovered 
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